UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 112

Sortiert nach

New agents for endocrine resistance in breast cancer

Breast (Edinburgh), 2017-08, Vol.34, p.1-11

2017

Link zum Volltext

Verfügbarkeit prüfen

Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer

Breast (Edinburgh), 2018-06, Vol.39, p.14-18

2018

Link zum Volltext

Verfügbarkeit prüfen

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis

ESMO open, 2020-08, Vol.5 (4), p.e000842, Article e000842

2020

Link zum Volltext

Verfügbarkeit prüfen

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer

NPJ breast cancer, 2022-07, Vol.8 (1), p.87-87, Article 87

2022

Link zum Volltext

Verfügbarkeit prüfen

Breast cancer treatment-induced cardiotoxicity

Expert opinion on drug safety, 2017-09, Vol.16 (9), p.1021-1038

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-10-09: Association between pertuzumab (P) induced diarrhea and skin rash and survival outcomes in patients (pts) with HER2-positive metastatic breast cancer enrolled in the CLEOPATRA trial

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P4-P4-10-09

2020

Link zum Volltext

Verfügbarkeit prüfen

Retrospective study of neuroendocrine breast cancer cases from a single institution in Québec

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e12588-e12588

2019

Link zum Volltext

Verfügbarkeit prüfen

Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial

European journal of cancer (1990), 2021-02, Vol.144, p.351-359

2021

Link zum Volltext

Verfügbarkeit prüfen

Patients' perspectives and safety of COVID-19 vaccination among cancer patients: A prospective single-center study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e24043-e24043

2022

Link zum Volltext

Verfügbarkeit prüfen

Reply to the letter “Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association”

Breast (Edinburgh), 2018-06, Vol.39, p.151-152

2018

Link zum Volltext

Verfügbarkeit prüfen

Concordance between liquid and tissue biopsy in participants with newly diagnosed recurrent breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.1028-1028

2023

Link zum Volltext

Verfügbarkeit prüfen

Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial

Journal of the National Comprehensive Cancer Network, 2021-02, Vol.19 (2), p.181

2021

Link zum Volltext

Verfügbarkeit prüfen

Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis

ESMO open, 2018, Vol.3 (4), p.e000361-e000361, Article e000361

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer

Breast (Edinburgh), 2018-02, Vol.37, p.142-147

2018

Link zum Volltext

Verfügbarkeit prüfen

The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.524-524

2021

Link zum Volltext

Verfügbarkeit prüfen

PARP inhibitors (PARPi) for the treatment of BRCA -mutated HER2-negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e13098-e13098

2018

Link zum Volltext

Verfügbarkeit prüfen

Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis

Cancer treatment reviews, 2018-01, Vol.62, p.123-132

2018

Link zum Volltext

Verfügbarkeit prüfen

Adherence to guidelines in requesting Oncotype DX in a publicly funded health care system

Current oncology (Toronto), 2018-08, Vol.25 (4), p.e311-318

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.10067-10067

2018

Link zum Volltext

Verfügbarkeit prüfen

Retrospective Analysis of Advanced Luminal Breast Cancer Patients Treated with Endocrine Therapy (ET) and Palbociclib Within a Compassionate Use Programme

Breast (Edinburgh), 2017-11, Vol.36, p.S48

2017

Link zum Volltext

Verfügbarkeit prüfen

PO75 - Retrospective Analysis of Advanced Luminal Breast Cancer Patients Treated with Endocrine Therapy (ET) and Palbociclib Within a Compassionate Use Programme

Breast (Edinburgh), 2017-11, Vol.36, p.S48-S48

2017

Link zum Volltext

Verfügbarkeit prüfen

Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.10065-10065

2018

Link zum Volltext

Verfügbarkeit prüfen

Adverse Events (AE) of Targeted Agents Added to Endocrine Therapy in Patients with Hormone Receptor-positive Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

Breast (Edinburgh), 2017-11, Vol.36, p.S43-S44

2017

Link zum Volltext

Verfügbarkeit prüfen

PO66 - Adverse Events (AE) of Targeted Agents Added to Endocrine Therapy in Patients with Hormone Receptor-positive Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

Breast (Edinburgh), 2017-11, Vol.36, p.S43-S44

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 112

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(103)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

New agents for endocrine resistance in breast cancer

Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer

Breast cancer treatment-induced cardiotoxicity

Abstract P4-10-09: Association between pertuzumab (P) induced diarrhea and skin rash and survival outcomes in patients (pts) with HER2-positive metastatic breast cancer enrolled in the CLEOPATRA trial

Retrospective study of neuroendocrine breast cancer cases from a single institution in Québec

Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial

Patients' perspectives and safety of COVID-19 vaccination among cancer patients: A prospective single-center study

Reply to the letter “Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association”

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials

Concordance between liquid and tissue biopsy in participants with newly diagnosed recurrent breast cancer

Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial

Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis

Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer

The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC)

PARP inhibitors (PARPi) for the treatment of BRCA -mutated HER2-negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis

Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis

Adherence to guidelines in requesting Oncotype DX in a publicly funded health care system

Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial

Retrospective Analysis of Advanced Luminal Breast Cancer Patients Treated with Endocrine Therapy (ET) and Palbociclib Within a Compassionate Use Programme

PO75 - Retrospective Analysis of Advanced Luminal Breast Cancer Patients Treated with Endocrine Therapy (ET) and Palbociclib Within a Compassionate Use Programme

Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials

Adverse Events (AE) of Targeted Agents Added to Endocrine Therapy in Patients with Hormone Receptor-positive Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

PO66 - Adverse Events (AE) of Targeted Agents Added to Endocrine Therapy in Patients with Hormone Receptor-positive Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

Suchergebnisse filtern